Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra M Swain

Showing results (81-90 of 210) with videos related to

Pageof 21
Sort By:
Cancer Biology & Therapy|December 7, 2007
Circulating biomarkers of bevacizumab activity in patients with breast cancerNeelima Denduluri, Sherry X Yang, Arlene W Berman, et al.
Journal of the National Cancer Institute|April 8, 2004
Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancerSandra M Swain, John W Wilson, Eleftherios P Mamounas, et al.
Breast Cancer Research and Treatment|October 14, 2006
A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-upJanice M Walshe, Arlene W Berman, Ujala Vatas, et al.
Breast Cancer Research and Treatment|August 29, 2016
Genomic profiling of breast cancer in African-American women using MammaPrintRaquel A Nunes, Lynette Wray, Mihriye Mete, et al.
The Oncologist|March 19, 2017
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular FunctionFilipa Lynce, Ana Barac, Ming T Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Changes in neurologic function tests may predict neurotoxicity caused by ixabepiloneJames J Lee, Jennifer A Low, Earllaine Croarkin, et al.
The Oncologist|May 30, 2014
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRASandra M Swain, Young-Hyuck Im, Seock-Ah Im, et al.
Journal of Oncology Practice|August 15, 2013
ASCO's approach to a learning health care system in oncologyGeorge W Sledge, Clifford A Hudis, Sandra M Swain, et al.
Oncology|July 28, 2007
A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancerMatthew L Goldman, Neelima Denduluri, Arlene W Berman, et al.
JCO Oncology Practice|May 11, 2023
Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health RecordsLetizia Polito, Jinjoo Shim, Sara A Hurvitz, et al.
Pageof 21

Showing results (81-90 of 210) with videos related to

Sort By:
Pageof 21
Cancer Biology & Therapy|December 7, 2007
Circulating biomarkers of bevacizumab activity in patients with breast cancerNeelima Denduluri, Sherry X Yang, Arlene W Berman, et al.
Journal of the National Cancer Institute|April 8, 2004
Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancerSandra M Swain, John W Wilson, Eleftherios P Mamounas, et al.
Breast Cancer Research and Treatment|October 14, 2006
A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-upJanice M Walshe, Arlene W Berman, Ujala Vatas, et al.
Breast Cancer Research and Treatment|August 29, 2016
Genomic profiling of breast cancer in African-American women using MammaPrintRaquel A Nunes, Lynette Wray, Mihriye Mete, et al.
The Oncologist|March 19, 2017
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular FunctionFilipa Lynce, Ana Barac, Ming T Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Changes in neurologic function tests may predict neurotoxicity caused by ixabepiloneJames J Lee, Jennifer A Low, Earllaine Croarkin, et al.
The Oncologist|May 30, 2014
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRASandra M Swain, Young-Hyuck Im, Seock-Ah Im, et al.
Journal of Oncology Practice|August 15, 2013
ASCO's approach to a learning health care system in oncologyGeorge W Sledge, Clifford A Hudis, Sandra M Swain, et al.
Oncology|July 28, 2007
A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancerMatthew L Goldman, Neelima Denduluri, Arlene W Berman, et al.
JCO Oncology Practice|May 11, 2023
Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health RecordsLetizia Polito, Jinjoo Shim, Sara A Hurvitz, et al.
Pageof 21